drugset / Trial / NCT00009958

Vaccine Therapy With or Without Sargramostim in Treating Patients With Cancer

NCT00009958

Phase 1 Terminated 42 enrolled National Cancer Institute (NCI)
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Phase I trial to compare the effectiveness of vaccine therapy with or without sargramostim in treating patients who have solid tumors. Vaccines may make the body build an immune response to kill tumor cells. Combining colony-stimulating factors such as sargramostim with vaccines may kill more tumor cells.

Timeline

Start
2000-11
Primary completion
2010-04
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject rF-CEA(6D)-TRICOM Vaccine Subcutaneous
Subject recombinant vaccinia-CEA(6D)-TRICOM vaccine Vaccine Other
Subject sargramostim Protein / enzyme biologic Subcutaneous